{'fraction_non_alphanumeric': 0.02329075882794891, 'fraction_numerical': 0.009015777610818933, 'mean_word_length': 4.6680851063829785, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Atorvastatin in clinically-significant macular edema in diabetics with a normal lipid profile.

INTRODUCTION
Lipid-lowering drugs preserve vision and reduce the risk of hard exudates in clinically-significant macular edema(CSME) in diabetics with an abnormal lipid profile. But their role in reducing CSME in diabetics with a normal lipid profile is not yet known.


OBJECTIVE
To evaluate the role of atorvastatin in CSME in diabetics with a normal lipid profile.


MATERIALS AND METHODS
A prospective, randomized clinical trial was carried out. Thirty CSME patients with a normal lipid profile were randomly divided into Group A and B. Atorvastatin had been started in Group A four weeks prior to laser treatment. The main outcome measures were any improvement or deterioration in visual acuity and macular edema and hard exudates at six months follow-up.


STATISTICS
Both the groups were compared using unpaired t test for quantitative parameters and chi-square test for qualitative parameters. A p value of less than 0.05 was taken as significant.


RESULTS
Visual acuity, macular edema and hard exudates resolution was not significantly different in the two groups (P = 0.14, 0.62, 0.39 respectively).


CONCLUSION
Atorvastatin does not affect treatment outcome in CSME with a normal lipid profile over a short term follow-up.